Olema Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

OLMA$7.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at June 30, 2024	57,246,411	$4	$594,261	$(118)	(366,984)	$227,163
Stock-based compensation expense	—	—	5,572	—	—	5,572
Employee stock purchase plan expense	—	—	54	—	—	54
Exercise of stock options	41,908	—	95	—	—	95
Net unrealized gain on marketable securities	—	—	—	582	—	582
Net loss	—	—	—	—	(34,555)	(34,555)
Balances at September 30, 2024	57,288,319	$4	$599,982	$464	(401,539)	$198,911
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income	Deficit	Equity
Balances at December 31, 2023	54,992,784	$4	$559,176	$347	(305,632)	$253,895
Issuance of shares under at-the-market offering, net of issuance costs of $166	1,772,278	—	22,787	—	—	22,787
Stock-based compensation expense	—	—	15,818	—	—	15,818
Exercise of stock options	359,897	—	1,110	—	—	1,110
Issuance of shares under the employee stock purchase plan	70,701	—	650	—	—	650
Employee stock purchase plan expense	—	—	441	—	—	441
Vesting of restricted stock awards	92,659	—	—	—	—	—
Net unrealized gain on marketable securities	—	—	—	117	—	117
Net loss	—	—	—	—	(95,907)	(95,907)
Balances at September 30, 2024	57,288,319	$4	$599,982	$464	(401,539)	$198,911

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at June 30, 2023	41,122,482	$3	$419,456	$(518)	$(257,358)	$161,583
Issuance of shares under equity private placement, net of issuance costs of $240	13,211,381	1	129,759	—	—	129,760
Stock-based compensation expense	—	—	4,019	—	—	4,019
Exercise of stock options	213,675	—	891	—	—	891
Employee stock purchase plan expense	—	—	86	—	—	86
Vesting of early exercised stock options	4,660	—	20	—	—	20
Vesting of restricted stock awards	49,318	—	—	—	—	—
Net unrealized gain on marketable securities	—	—	—	277	—	277
Net loss	—	—	—	—	(21,502)	(21,502)
Balances at September 30, 2023	54,601,516	$4	$554,231	$(241)	(278,860)	$275,134
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balances at December 31, 2022	40,287,097	$3	$408,333	$(1,813)	$(208,977)	$197,546
Issuance of shares under equity private placement, net of issuance costs of $240	13,211,381	1	129,759	—	—	129,760
Stock-based compensation expense	—	—	12,574	—	—	12,574
Exercise of stock options	665,902	—	2,443	—	—	2,443
Issuance of shares under employee stock purchase plan	270,541	—	711	—	—	711
Employee stock purchase plan expense	—	—	331	—	—	331
Vesting of early exercised stock options	18,640	—	80			80
Vesting of restricted stock awards	147,955	—	—	—	—	—
Net unrealized gain on marketable securities	—	—	—	1,572	—	1,572
Net loss	—	—	—	—	(69,883)	(69,883)
Balances at September 30, 2023	54,601,516	$4	$554,231	$(241)	(278,860)	$275,134

Condensed Consolidated Statements of Cash Flows

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.